Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072486 · ClinicalTrials.gov registry record · NA
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A NA study of Advanced Adult Hepatocellular Carcinoma and Stage IIIA Hepatocellular Carcinoma, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02072486 is a NA study of Advanced Adult Hepatocellular Carcinoma and Stage IIIA Hepatocellular Carcinoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 30 participants, above the 27-participant average among 3 other Advanced Adult Hepatocellular Carcinoma trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02072486, a NA study of Advanced Adult Hepatocellular Carcinoma and Stage IIIA Hepatocellular Carcinoma, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Sorafenib tosylate may block some of the enzymes needed for tumor cell growth. Blocking these enzymes may also help the immune system work better. Granzyme B is a biomarker that can be used to measure how well the immune system is working. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. Studying granzyme B levels in patients receiving sorafenib tosylate may help doctors learn more about the effects of sorafenib tosylate on the immune system and may help to predict how well sorafenib tosylate will work in treating patients with liver cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Sorafenib Tosylate
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-11-18 |
| Est. Completion | 2020-07-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072486
The ClinicalTrials.gov registry entry for NCT02072486 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 27-participant average among 3 other Advanced Adult Hepatocellular Carcinoma trials with a reported enrollment target (11% higher). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Advanced Adult Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02072486 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02072486 about?
NCT02072486 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". This clinical trial studies sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Sorafenib tosylate may block some of the enzymes needed for tumor cell growth. Blocking these enzymes may also help the immune system work better. Granzyme B is a biomarker that c...
What is the current status of trial NCT02072486?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-11-18. Estimated completion is 2020-07-19.
What conditions does trial NCT02072486 study?
This clinical trial studies the following conditions: Advanced Adult Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma.
What interventions are being tested in trial NCT02072486?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT02072486?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02072486 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
COMPLETED · Phase 1
-
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Advanced Adult Hepatocellular Carcinoma
All registered trials for this condition
Stage IIIA Hepatocellular Carcinoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.